Healthcare Industry News: TrueBeam
News Release - January 17, 2019
First Cancer Patients in Taiwan Treated with Varian HyperArc High-Definition RadiotherapyPALO ALTO, Calif., Jan. 17, 2019 -- (Healthcare Sales & Marketing Network) -- Varian (NYSE: VAR) announced 10 patients at the Chi Mei Medical Center with brain lesions became the first patients in Taiwan to be treated using the company's HyperArc™ High Definition Radiotherapy (HDRT), a new type of radiosurgery treatment solution.
"We are excited that HyperArc treatments have begun in Taiwan," said Christina Lin, managing director Taiwan for Varian's Oncology Systems business. "By working closely with leading institutions like Chi Mei Hospital to deliver advanced cancer treatments to more patients, we are taking another important step in achieving our vision of a world without fear of cancer."
The HyperArc solution is designed to automate and simplify sophisticated treatments such as stereotactic radiosurgery (SRS), and capitalizes on the unique capabilities of Varian's TrueBeam® and EDGE™ treatment systems. HyperArc treatments allow clinicians the ability to deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue. These advanced treatments can be delivered in a conventional treatment time slot. The treatment planning for the HyperArc solution is supported by Varian's Eclipse™ treatment planning software and ARIA® oncology information system.
For more information on the HyperArc solution, visit www.varian.com/hyperarc
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.